a drug that reduces prostate hyperplasia.

Prostate volume reduction drugs are mainly 5α-reductase inhibitors. Age and androgens are two important factors in the pathogenesis of prostate hyperplasia. Dihydrotestosterone is the main androgen in prostate tissue, which plays an important role in prostate growth, development and hyperplasia. Prostate is rich in 5α-reductase, which can convert testosterone from blood circulation into dihydrotestosterone. 5α-reductase inhibitors inhibit the activity of 5α-reductase, reduce the amount of testosterone converted to dihydrotestosterone, thus reducing prostate volume, improving urination symptoms, increasing urinary flow rate, and delaying disease progression. Therefore, 5α-reductase inhibitors are commonly used in the treatment of benign prostatic hyperplasia at this stage, and the most common drugs are finasteride, dutasteride, etc. However, these drugs take effect slowly, generally effective in about 3 months after taking medicine, symptoms are easy to relapse after stopping medicine, need to take medicine for a long time, the effect on the prostate with large volume is more obvious.